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A MODEL OF PRIMARY CARE TREATMENT OF
MAJOR DEPRESSIVE DISORDER
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Major depressive disorder (MDD) is one of the most
prevalent mental disorders in the US with social costs up-
wards of $43 billion. The Agency for Health Care Policy
and Research has disseminated diagnosis and manage-
ment guidelines for MDD in primary care.
OBJECTIVE: Our aim was to develop a simulation
model to evaluate clinical and economic consequences of
following AHCPR treatment recommendations. A sec-
ondary objective was to create a tool that could be used
by health plan decision-makers to assess the value of al-
ternative treatments for MDD.
METHODS: A discrete state simulation model was devel-
oped to evaluate primary care management of adults with
MDD following the AHCPR guidelines. The perspective
of the model was that of the health plan; the time horizon
was 1 year from the initiation of pharmacotherapy. Un-
certainty was evaluated using Monte Carlo simulation
techniques. Endpoints included clinical remission, hospi-
talization for MDD, or psychiatric referral for treatment
failure. Efficacy and safety data were drawn from pub-
lished randomized, nonrandomized, and synthesized
studies, and cost data were derived from modal reim-
bursement rates from a large managed care organization
in Washington state.
RESULTS: The results of the base case simulation dem-
onstrated that initial treatment of MDD with serotonin
reuptake inhibitors provided better clinical outcomes at
similar costs when compared to tricyclic antidepressants.
CONCLUSION: Simulation models of treatment guide-
lines are an important and useful extension of outcomes
research because they can simultaneously account for
costs and effectiveness not otherwise available from a sin-
gle published study. Further, models such as this can
prove useful to health plan decision-makers interested in
the ex ante evaluations of individual antidepressant
agents for formulary decisions.
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MEDICAL AND ECONOMIC OUTCOMES OF
NONCOMPLIANCE WITH DILANTIN IN
ADULT MEDICAID EPILEPTICS
Singer ME
Case Westem Reserve University, Cleveland, OH, USA
Noncompliance with medication may be the biggest
cause of epileptic seizures. Compliance enhancement pro-
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grams can be expensive. Decision makers need data on
the outcomes and cost due to noncompliance.
OBJECTIVE: To examine the medical and economic con-
sequences of noncompliance in Medicaid adults whose
epilepsy is under control when taking medication.
METHODS: Ohio Medicaid claims files for 1994-1995
were used. Patients were ages 25-59, continuously en-
rolled, ?1 diagnosis of epilepsy in 1994. Missed prescrip-
tions (Rx's) were defined as the number of calendar
months with no prescriptions. We included patients with
Rx's for 100 mg extended release dilantin in each month
of 1994, with no ED/hospitalizations in 1994. ED visits
and hospitalizations were counted if the primary dx was
epilepsy or convulsions. Patients were excluded if they
filled a Rx for any other anticonvulsant, or if they had
>6 missed Rx's in 1995. Ordinary, logistic, ordinal legis-
tic and Poisson regression models were fit to relate missed
Rx's in 1995 to the number of ED/hospitalizations. Ad-
justors included age, sex, race, and average dose. Medi-
caid reimbursements associated with acute care episodes
were tallied. Net cost (to Medicaid) of missed Rx's was
computed.
RESULTS: 22/193 patients accounted for 38 ED/hospi-
talizations. All models produced similar results, with
missed Rx's being statistically significant (p < .01). Each
missed Rx was associated with an increase of .144 (CI,
.033-.255) acute care episodes (odds ratio across models
ranged 1.83-2.00). Mean reimbursement per monthly Rx
was $44.94. Mean reimbursement per episode was
$1424.81. Net cost to Medicaid per missed Rx was
$160.23, or $5.27 per missed day.
CONCLUSIONS: Noncompliance in medication con-
trolled epilepsy is costly to Medicaid. Compliance en-
hancement programs in this population may be cost sav-




PRESCRIBING FOR THE ELDERLY
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With the widespread use of psychotropics in the elderly,
issues related to the availability and appropriate use of
psychotropic medications in older patients have become a
concern from both therapeutic and economic viewpoints.
OBJECTIVE: The purpose of this study was to examine
the factors predicting potentially inappropriate psycho-
tropic prescribing for the elderly in office-based practice.
METHODS: This study utilized data from the National
Ambulatory Medical Care Survey (NAMCS) 1995 to ex-
amine psychotropic agents that should be generally
avoided in the elderly, based on the criteria previously de-
veloped through a consensus process. These included di-
azepam, chlordiazepoxide, meprobamate, flurazepam,
pentobarbital, secobarbital, and amitriptyline. Psychotro-
